The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia
Abstract
Background — This phase 1/2 study investigated the safety of percutaneous catheter-based gene transfer of naked plasmid DNA encoding for vascular endothelial growth factor 2 (phVEGF2) to left ventricular (LV) myocardium in a prospective, randomized, double-blind, placebo-controlled, dose-escalating study of inoperable patients with class III or IV angina. Methods and Results — A steerable deflectable 8F catheter with a 27-gauge needle at its distal tip was advanced percutaneously to the endocardial surface of the LV in 19 patients (age, 61±2 years) with chronic myocardial ischemia who were not candidates for conventional revascularization. Patients were randomized in a double-blind fashion to receive 6 injections (total volume, 6.0 mL) of placebo or phVEGF2 in doses of 200 μg (n=9), 800 μg (n=9), or 2000 μg (n=1) guided by LV electromechanical (NOGA) mapping with a gene-to-placebo ratio of 2:1. A total of 114 LV injections were delivered and caused no hemodynamic alterations, sustained ventricular arrhythmias, ECG evidence of infarction, or ventricular perforation. End-point analysis at 12 weeks disclosed a statistically significant improvement in Canadian Cardiovascular Society (CCS) angina class in phVEGF2-treated versus placebo-treated patients (−1.3 versus −0.1, P =0.04). Remaining efficacy end points—including change in exercise duration (91.8 versus 3.9 seconds), functional improvement by ≥2 CCS classes (9 of 12 versus 1 of 6), and Seattle Angina Questionnaire data—all showed strong trends favoring efficacy of phVEGF2 versus placebo treatment. Conclusions — This phase 1/2, double-blind, randomized trial provides preliminary data that support safety of phVEGF2 catheter-mediated myocardial gene transfer. The statistically significant reduction in anginal class and strong positive trends for remaining end points suggest that a larger phase 2/3 trial is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Letter: Grading of angina pectoris.
Campeau, L. (1976) · Circulation · doi:10.1161/circ.54.3.947585 · Cited by 1,601
Baumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.12.1114 · Cited by 1,098
Self-citationLosordo, D. W., Vale, P. R., Symes, J. F., Dunnington, C. H., Esakof, D. D., Maysky, M., Ashare, A. B., Lathi, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.98.25.2800 · Cited by 987
Self-citationGepstein, L., Hayam, G., & Ben-Haim, S. A. (1997) · Circulation · doi:10.1161/01.cir.95.6.1611 · Cited by 759
Rosengart, T. K., Lee, L. Y., Patel, S. R., Sanborn, T. A., Parikh, M., Bergman, G. W., Hachamovitch, R., Szulc, M., Kligfield, P. D., Okin, P. M., et al. (1999) · Circulation · doi:10.1161/01.cir.100.5.468 · Cited by 656
Virus treatment questioned after gene therapy death
Lehrman, S. (1999) · Nature · doi:10.1038/43977 · Cited by 576
Dilsizian, V, & Bonow, R. O. (1993) · Circulation · doi:10.1161/01.cir.87.1.1 · Cited by 553
Giordano, F. J., Ping, P., McKirnan, M. D., Nozaki, S., Demaria, A. N., Dillmann, W. H., Mathieu-Costello, O., & Hammond, H. K. (1996) · Nature Medicine · doi:10.1038/nm0596-534 · Cited by 486
Wijns, W., Vatner, S. F., & Camici, P. G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807163390307 · Cited by 428
Isner, J. M., Baumgartner, I., Rauh, G., Schainfeld, R., Blair, R., Manor, O., Razvi, S., & Symes, J. F. (1998) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(98)70022-9 · Cited by 392
Self-citation
Cited by
Nonviral Gene Delivery: Principle, Limitations, and Recent Progress
Al-Dosari, M. S., & Gao, X. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9143-y · Cited by 706
The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF
Sadat, S., Gehmert, S., Song, Y.-H., Yen, Y., Bai, X., Gaiser, S., Klein, H., & Alt, E. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.058 · Cited by 300
Pepe, M., Mamdani, M., Zentilin, L., Csiszar, A., Qanud, K., Zacchigna, S., Ungvari, Z., Puligadda, U., Moimas, S., Xu, X., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.220855 · Cited by 93
Metadata
- Authors
- Losordo, D. W., Vale, P. R., Hendel, R. C., Milliken, C. E., Fortuin, F. D., Cummings, N., Schatz, R. A., Asahara, T., Isner, J. M., & Kuntz, R. E.
- Venue
- Circulation
- Published
- 2002-04-30
- Volume
- 105
- Issue
- 17
- Pages
- 2012-2018
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2124715674
- Cited by
- 466
- References
- 23
- FWCI
- 48.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia. https://app.cochat.ai/papers/10.1161/01.cir.0000015982.70785.b7
- The paper
- Losordo, D. W., Vale, P. R., Hendel, R. C., Milliken, C. E., Fortuin, F. D., Cummings, N., Schatz, R. A., Asahara, T., Isner, J. M., & Kuntz, R. E. (2002). Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia. Circulation. https://doi.org/10.1161/01.cir.0000015982.70785.b7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.